Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 26, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Relapsed/refractory diffuse large B-cell lymphoma.

Jonathan W Friedberg1

  • 1James P Wilmot Cancer Center and University of Rochester, Rochester, NY 14642, USA. jonathan_friedberg@urmc.rochester.edu

Hematology. American Society of Hematology. Education Program
|December 14, 2011
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and Validation of a Novel Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma.

American journal of hematology·2026
Same author

Diagnosis-to-treatment interval is associated with outcomes in follicular lymphoma treated with immunochemotherapy.

Blood·2026
Same author

Brentuximab vedotin and dose attenuated chemoimmunotherapy for patients 75 years and older with diffuse large B-cell lymphoma with analysis of outcomes by frailty.

Journal of geriatric oncology·2026
Same author

Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy: 15-Year Follow-Up of the SWOG S0016 Trial.

JAMA oncology·2026
Same author

Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma.

Leukemia·2026
Same author

Patterns of care and clinical outcomes in systemic peripheral T-cell lymphoma: the LEO-MER prospective cohort study.

Blood advances·2026
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Peri-transplant conundrums: optimizing maintenance therapy using MRD-directed approaches.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) presents challenges, with novel therapies emerging. Patients ineligible for high-dose therapy and autologous stem cell transplantation (HD-ASCT) need clinical trials for targeted agents.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Diffuse large B-cell lymphoma (DLBCL) remains a significant cause of cancer morbidity and mortality, with approximately one-third of patients experiencing relapsed or refractory disease.
  • Gene-expression analyses have elucidated mechanisms of chemotherapy resistance in DLBCL, identifying potential targets for novel therapeutic strategies.
  • Current treatment paradigms for relapsed/refractory DLBCL include high-dose therapy and autologous stem cell transplantation (HD-ASCT) for eligible patients.

Purpose of the Study:

  • To review the current understanding and management of relapsed/refractory diffuse large B-cell lymphoma.
  • To highlight the limitations of existing therapies, particularly HD-ASCT, in specific patient populations.
  • To emphasize the need for novel therapeutic approaches, including targeted agents, for patients not eligible for ASCT.

Related Experiment Videos

Last Updated: May 26, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Main Methods:

  • Review of recent clinical trial data, including the CORAL study.
  • Analysis of gene-expression findings related to chemotherapy resistance in DLBCL.
  • Discussion of current and future therapeutic strategies for relapsed/refractory DLBCL.

Main Results:

  • Patients with DLBCL refractory to rituximab-containing regimens may have poorer outcomes with HD-ASCT.
  • Improvements in HD-ASCT, such as novel conditioning regimens and maintenance strategies, are under investigation.
  • A significant proportion of DLBCL patients are ineligible for HD-ASCT due to disease characteristics or comorbidities.

Conclusions:

  • HD-ASCT remains a curative option for select patients with relapsed/refractory DLBCL without comorbidities.
  • The majority of patients not eligible for HD-ASCT face incurable disease, necessitating enrollment in clinical trials.
  • Targeted agents informed by molecular insights represent a critical future direction for treating DLBCL patients ineligible for stem cell transplantation.